Wanbury: Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil…
Wanbury (WANBURY) filed a disclosure titled "Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade". The company is valued at about ₹699 crore.
What happened
Wanbury (WANBURY) filed a disclosure with the exchanges on 12 November 2026 at 11:21 AM titled "Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade".
Company snapshot
Wanbury is a micro-cap company, with a market value of about ₹699 crore.
The stock last traded at ₹199.8, against a 52-week range of ₹161.5–₹358.9 (44.3% below the high).
Before this filing the shares had moved +3.4% over the month and −21.1% over three months. Average daily turnover over the last 20 sessions was about ₹3.54 crore.
Promoters held 42.98% at the end of Q2 FY27, down 0.04% points from the previous quarter; 5.49% of promoter shares were pledged. Foreign institutions owned 0.71% and domestic institutions 0.02%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 160 | 15.2 | 4.58 |
| Q3 FY26 | 162 | 15.8 | 4.52 |
| Q4 FY26 | 165 | 21.7 | 7.33 |
| Q1 FY27 | 166 | 3.2 | 0.93 |
| Q2 FY27 | 183 | 9.1 | 2.44 |
What history shows
This is not the company's first approval disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 3.4% on average the next trading day and was down 9.2% on average after five days (2 filings with price data).
Market-wide, 1,619 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 30 Jul 2026 | A press release dated July 30, 2026, titled "Fully Compliant - No… | −4.0% | −10.3% |
| 20 Jul 2026 | Intimation Of Completion Of Inspection By The United States Food And… | −2.7% | −8.1% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Wanbury Limited Q2 Revenue Rises 14.3% to ₹182.91 Crore
- Wanbury Q2FY27 Results: Net profit falls 21.7% YoY to ₹11.9 crore
- Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
- Wanbury Q2 Results FY27: Revenue Up 14.28% to Rs 182.91 Cr, PAT Rs 11.88 Cr
- Wanbury Q2 profit rebounds to Rs 11.9 crore sequentially
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.